- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05151380
Clinical and Cyto-histological Evaluation of Fractional CO2 Laser Treatment on Genito-Urinary Syndromes of Menopause Related to Vaginal Atrophy (ATROVENANS)
Evaluation Clinique et Cyto-histologique du Traitement Laser CO2 fractionné Sur Les Syndromes Génito-Urinaires de la Ménopause liés à l'Atrophie Vaginale
Estrogen deficiency can occur naturally during menopause or as a secondary effect of various treatments for breast or pelvic cancer and can lead to very disabling vulvovaginal symptoms, since it is associated with an anatomical and functional cellular modification of the urogenital sphere. These changes result in urogenital atrophy responsible for vaginal dryness, painful intercourse (dyspareunia), discomfort, itching and burning sensations, dysuria, urgency and incontinence. These symptoms, which significantly affect quality of life, are found in more than 40% of menopausal women and are grouped under the term Genitourinary Syndrome of Menopause (GSM). General or local estrogen-based treatments improve patients' symptoms, but remain contraindicated in women who have had breast cancer. Non-estrogenic local treatments are less effective, remain restrictive and are therefore often abandoned.
The CO2 laser is currently part of the therapeutic arsenal for the management of patients with GSM. This device prevents and eliminates the effects of low estrogen levels on vaginal tissue by restoring the characteristic conditions of the vaginal mucosa of a woman of childbearing age. This simple treatment, which lasts only a few minutes, is safe and painless and has no serious side effects. It restores the tone and elasticity of the tissues, with positive effects on the quality of life and the couple's relationship. The investigators wish to evaluate the possible changes of the genital sphere in a longitudinal way (before, during and after the treatment), including the induced cytohistological changes, in patients with GSM who can benefit of this therapy.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Trévenans, France, 90400
- Hôpital Nord Franche-Comté
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women over 40 years of age
- Patients with natural menopause or menopause secondary to cancer treatment (breast, pelvis or other)
- Patients with vaginal and/or urinary, non-vulvar GSM
- Patients for whom CO2 laser therapy is proposed
Exclusion Criteria:
- Vulvovaginal infections (vaginosis)
- Uninvestigated vaginal hemorrhage
- Herpes
- Pregnancy or breastfeeding
- Cervico-vaginal pathology (cervical and/or vaginal dysplasia)
- Suspected or diagnosed HPV
- Significant vaginal prolapse
- Patients on hormone replacement therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Women with CO2 laser MonaLisa Touch ® sessions
Women with 3 sessions of CO2 laser MonaLisa Touch ®
|
3 sessions of SmartXide fractional CO2 laser via the MonaLisa Touch® device, spaced 4 weeks apart, will be performed. An additional comfort session will be performed at 1 year if needed. The handpiece of the MonaLisa Touch® device is applied to the vaginal walls with a 360° scan, between 800 and 1100µs, to the vaginal orifice |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The main objective of the study is to analyze the evolution of GSM by the use of the MonaLisa Touch ® fractionated laser.
Time Frame: 3 months
|
The primary endpoint is the comparison of the patient's clinical score composed of a visual analogic scale measuring the intensity of symptoms related to vaginal atrophy (i.e., vaginal burning, vaginal pruritus, vaginal dryness, dyspareunia, and dysuria), before and after 3 laser sessions.
|
3 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-A01625-36
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Genitourinary Syndrome of Menopause
-
University of California, IrvineRecruitingGenitourinary Syndrome of MenopauseUnited States
-
Michigan Institution of Women's Health PCCompletedGenitourinary Syndrome of MenopauseUnited States
-
Stratpharma AGRecruitingGenitourinary Syndrome of MenopauseUnited States
-
EgymedicalpediaCompleted
-
Maltepe UniversityCompletedGenitourinary Syndrome of MenopauseTurkey
-
Centro de Atenção ao Assoalho PélvicoRecruitingGenitourinary Syndrome of MenopauseBrazil
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedGenitourinary Syndrome of MenopauseItaly
-
King's College Hospital NHS TrustAlexandra Hospital, Athens, GreeceCompleted
-
Kanuni Sultan Suleyman Training and Research HospitalRecruitingGenitourinary Syndrome of MenopauseTurkey
-
Hacettepe UniversityCompletedGenitourinary Syndrome of MenopauseTurkey
Clinical Trials on CO2 laser MonaLisa Touch ®
-
University Hospital Inselspital, BerneDeka Medical, Inc.Active, not recruitingLichen Sclerosus Et Atrophicus of the VulvaSwitzerland
-
Hvidovre University HospitalCompleted
-
Royal North Shore HospitalUnknownVulvovaginal Atrophy | Genitourinary Symptoms and Ill-Defined ConditionsAustralia
-
National and Kapodistrian University of AthensCompletedOveractive Bladder (OAB)Greece
-
National and Kapodistrian University of AthensIRCCS San RaffaeleUnknown
-
National and Kapodistrian University of AthensUnknownVaginal Dryness | Dyspareunia | Gynecological Cancer | Pelvic RadiotherapyGreece
-
National and Kapodistrian University of AthensUnknownBreast Cancer | Vaginal Atrophy | Dyspareunia | Genitourinary Syndrome of MenopauseGreece
-
Federal University of São PauloFundação de Amparo à Pesquisa do Estado de São PauloEnrolling by invitationGenitourinary Symptoms | Postmenopausal Symptoms | Postmenopausal Atrophic VaginitisBrazil
-
Faculdade de Medicina do ABCCompleted
-
Mount Sinai Hospital, CanadaWithdrawnBreast Cancer Female | Genitourinary Syndrome of Menopause